Clarithromycin therapy for patients with Cystic Fibrosis: A randomized controlled trial

Robinson, P., Schechter, Michael S., Sly, Peter D., Winfield, Kaye, Smith, Julie, Brennan, Siobhain, Shinkai, Masaharu, Henke, Markus O. and Rubin, Bruce K. (2012) Clarithromycin therapy for patients with Cystic Fibrosis: A randomized controlled trial. Pediatric Pulmonology, 47 6: 551-557. doi:10.1002/ppul.21613


Author Robinson, P.
Schechter, Michael S.
Sly, Peter D.
Winfield, Kaye
Smith, Julie
Brennan, Siobhain
Shinkai, Masaharu
Henke, Markus O.
Rubin, Bruce K.
Title Clarithromycin therapy for patients with Cystic Fibrosis: A randomized controlled trial
Journal name Pediatric Pulmonology   Check publisher's open access policy
ISSN 8755-6863
1099-0496
Publication date 2012-06
Sub-type Article (original research)
DOI 10.1002/ppul.21613
Volume 47
Issue 6
Start page 551
End page 557
Total pages 7
Place of publication Hoboken, NJ, United States
Publisher John Wiley & Sons
Collection year 2013
Language eng
Formatted abstract
The clinically significant actions of oral azithromycin in modifying progressive cystic fibrosis (CF) lung disease have been well documented. In vitro and clinical data suggests that clarithromycin has immunomodulatory properties similar to other 14-member macrolides, however two previously reported short term, open label trials of clairthromycin in small numbers of patients with CF failed to show significant benefits in modifying lung function or inflammation. We performed an international double blind, cross-over trial in which 63 subjects with CF were studied while receiving either placeo or 500 mg oral clarithromycin twice daily for 5 months, with a 1-month wash-out. The primary efficacy end point was the change in lung function (FEV1 and FVC) during the clarithromycin treatment period compared to placebo treatment. Secondary efficacy end points included; quality of life, number of pulmonary exacerbations, height and weight, sputum inflammatory mediator content, sputum transportability and surface properties, bacterial flora, nasal potential difference, and breath condensate. No significant difference in either the primary efficacy end point or any secondary end point was seen during the period of clarithromycin treatment compared to those seen during placebo administration. We conclude that clarithromycin is not effective in treating CF lung disease.
Keyword Clarithromycin
Cystic Fibrosis
Cytokines
Pulmonary Function
Quality of life
Immunomodulatory Medications
Diffuse Panbronchiolitis
Pseudomonas-Aeruginosa
Azithromycin
Erythromycin
Macrolides
Mechanisms
Il-8
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Official 2013 Collection
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 9 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 10 Jun 2012, 16:06:17 EST by System User on behalf of Child Health Research Centre